Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26647690 | 1.00 | JAK2 (0.52) | JAK2SIGMAR1JAK3LSSNOS1 | |
| SCHEMBL26647696 | 0.81 | JAK2 (0.45) | JAK2JAK3JAK1 | |
| SCHEMBL26647693 | 0.81 | JAK2 (0.45) | JAK2JAK3JAK1 | |
| SCHEMBL22214277 | 0.81 | JAK2 (0.44) | JAK2JAK3JAK1CYP1A2 | |
| SCHEMBL26772135 | 0.76 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL26772556 | 0.75 | PRMT5 (0.49) | JAK2JAK1 | |
| SCHEMBL25799063 | 0.75 | IL1B (0.51) | SIGMAR1LSSNOS1NOS2 | |
| SCHEMBL1074099 | 0.75 | JAK2 (0.47) | JAK2NOS1NOS2 | |
| SCHEMBL25799053 | 0.74 | IL1B (0.43) | SIGMAR1LSSNOS1NOS2MALT1 | |
| SCHEMBL22394131 | 0.74 | JAK2 (0.41) | JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304560-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. | 2025-10-02 | — | — | US | disclosed |
| EP-4522600-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546586-A | Modulators of NLRP3 inflammatory corpuscles and related products and methods | 纽摩拉治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230365534-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. | 2023-11-16 | — | — | US | disclosed |
| WO-2023220408-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304560-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NLRP3, NLRP1, PYCARD | JAK2 1552/4885SIGMAR1 1282/4885JAK3 1854/4885 |
| US-20230365534-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NLRP3, NLRP1, PYCARD | JAK2 1484/4885SIGMAR1 1238/4885JAK3 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.